Global Clinical Trials: What Changes When Your Supply Chain Crosses Borders

Running a clinical trial at a handful of sites in the U.S. is complicated enough. Running one across multiple countries and regulatory jurisdictions is a fundamentally different undertaking, and the supply chain complexity that comes with it is one of the most consistently underestimated aspects of global clinical development.

I've managed global clinical supply chains across programs that span multiple continents, and the pattern I see repeating is the same: companies plan their global trial strategy around the science and the patient populations, which is the right starting point. But the supply chain requirements for getting investigational product into each of those countries, and keeping it flowing reliably throughout the study, often don't get the attention they need until something goes wrong.

Every Country Has Its Own Rules

This sounds obvious, but the practical implications are enormous. Each country where you're running clinical sites has its own regulatory requirements for importing investigational medicinal product. And those requirements aren't just variations on a theme. They can be fundamentally different in ways that affect your labeling, your packaging configuration, your documentation, your release process, and your shipping timeline.

Country-specific labeling requirements are one of the most common areas where companies get caught off guard. Language requirements, required content, label formatting, and regulatory reference numbers all vary by country. A label that's compliant for U.S. clinical sites may need to be entirely redesigned for sites in the EU, and redesigned again for sites in Asia-Pacific. Each version needs regulatory review, artwork development, proofing, and quality approval. When you're supplying a trial across 15 or 20 countries, that labeling workstream alone can become a significant operational effort.

Import permits and licenses add another layer. Many countries require an import license or permit before investigational product can enter the country, and the application process for those permits can take weeks or months. Some require in-country representation through a local regulatory agent. Some require specific documentation that has to be prepared and certified before each shipment. If these requirements aren't identified and planned for early enough, you end up with product manufactured, packaged, and ready to ship, sitting in a warehouse because the import pathway isn't open yet.

Qualified Person release in the EU is another area that trips up companies unfamiliar with the process. In the EU, every batch of investigational medicinal product must be certified by a Qualified Person before it can be distributed to clinical sites. That QP release process has its own requirements, its own documentation, and its own timeline. It's a step that doesn't exist in the U.S. regulatory framework, and companies running their first EU clinical trial sometimes discover it later than they should.

Adding Countries Mid-Trial Is Where It Gets Hard

If planning global clinical supply from the start is complex, adding new countries to an ongoing trial is where the coordination challenge intensifies. Clinical operations wants to open new sites quickly to accelerate enrollment. Regulatory affairs is working through the country-specific submission requirements. And supply chain needs to figure out how to get compliant product to those new sites on a timeline that supports the enrollment plan.

The problem is that these three workstreams don't always move at the same pace. Clinical ops may identify a new country and begin the site activation process, but the supply chain requirements for that country, from labeling modifications to import permits to distribution logistics, have their own lead times that can't be compressed just because enrollment is behind schedule.

I've seen situations where a country was added to a trial and clinical operations expected product to be available at sites within weeks, while the actual supply chain lead time, once you account for country-specific labeling, regulatory documentation, import licensing, and shipping logistics, was closer to three or four months. That disconnect creates friction between functions and, more importantly, delays the enrollment that the country addition was supposed to accelerate.

The companies that handle this well build supply chain into the country-opening process from the beginning. Before a decision is made to add a country, supply chain provides a realistic timeline for what it takes to get compliant product to that market. That doesn't slow down the decision. It makes it an informed one.

The Landscape Keeps Shifting

What makes global clinical supply particularly challenging right now is that the regulatory and political landscape isn't standing still. Trade policies are changing. Import and export regulations are being updated. Tariff structures are shifting in ways that affect the cost and logistics of moving product across borders. Sanctions and geopolitical tensions are creating new restrictions on where and how pharmaceutical materials can be shipped.

For supply chain teams managing global clinical trials, this means the rules you planned around six months ago may not be the rules you're operating under today. A shipping lane that was straightforward last year may now require additional documentation or routing changes. A country that was easy to supply may now have new import requirements driven by changes in trade policy. A customs process that took days may now take weeks.

Staying current with these changes requires active monitoring and strong relationships with regulatory affairs, logistics partners, and in-country agents. It's not enough to set up your global supply chain at the start of a trial and assume it will run the same way for the duration of the study. The environment is dynamic, and the supply chain strategy needs to be dynamic with it.

Cross-Functional Coordination Is the Whole Game

If there's one theme that runs through every aspect of global clinical supply, it's that none of it works without tight cross-functional coordination. Clinical operations, regulatory affairs, supply chain, quality, and logistics all have to be aligned on timelines, requirements, and priorities. When one function moves without the others, the result is delays, rework, and unnecessary cost.

That coordination doesn't happen by accident. It requires a deliberate operating model: regular cross-functional meetings focused on supply status and upcoming country activations, shared visibility into timelines and dependencies, and clear escalation paths when things don't go as planned. In my experience, the companies that invest in this coordination infrastructure early spend far less time firefighting later.

Global clinical supply isn't glamorous work. It doesn't make it into press releases or investor presentations. But it's the operational backbone that determines whether your trial has product at the right site, in the right country, in the right configuration, at the right time. When it works, nobody notices. When it doesn't, everyone does.

Verant Consulting Group helps biotech companies build and manage global clinical supply chains, from country-specific regulatory planning to cross-functional coordination and logistics strategy. If you're running a global trial and need supply chain support, let's talk.